ATHENS
29-31
March
2018
29-31
March
2018
SPEAKERS
Edward A. Dennis
(University of California San Diego, USA)
Structure and function of the phospholipase A2 superfamily
(University of California San Diego, USA)
Structure and function of the phospholipase A2 superfamily
Gabor J. Tigyi
(University of Tennessee, USA)
The Autotaxin-LPA receptor axis in the regulation of cancer stem cells and the tumor microenvironment
(University of Tennessee, USA)
The Autotaxin-LPA receptor axis in the regulation of cancer stem cells and the tumor microenvironment
Makoto Murakami
(The University of Tokyo, Japan)
Updating the PLA2 knockout studies: immunity, metabolic disease, and beyond
(The University of Tokyo, Japan)
Updating the PLA2 knockout studies: immunity, metabolic disease, and beyond
Sasanka Ramanadham
(University of Alabama Birmingham, USA)
Impact of iPLA2b expression on T1D development
(University of Alabama Birmingham, USA)
Impact of iPLA2b expression on T1D development
Jesus Balsinde
(University of Valladolid, Spain)
Bioactive fatty acids and phospholipids of monocytes and macrophages
(University of Valladolid, Spain)
Bioactive fatty acids and phospholipids of monocytes and macrophages
Gerard Lambeau
(CNRS Sophia Antipolis, France)
From venom PLA2s to medical applications
(CNRS Sophia Antipolis, France)
From venom PLA2s to medical applications
Anna Nicolaou
(University of Manchester, UK)
Bioactive lipid mediators of cutaneous inflammation
(University of Manchester, UK)
Bioactive lipid mediators of cutaneous inflammation
Andrea Huwiler
(University of Bern, Switzerland)
Immunomodulatory effect of novel butterfly derivatives of fingolimod in experimental autoimmune encephalomyelitis in mice
(University of Bern, Switzerland)
Immunomodulatory effect of novel butterfly derivatives of fingolimod in experimental autoimmune encephalomyelitis in mice
Oliver Werz
(University of Jena, Germany)
Human macrophages differentially produce specific resolvin or leukotriene signals in response to pathogenic bacteria
(University of Jena, Germany)
Human macrophages differentially produce specific resolvin or leukotriene signals in response to pathogenic bacteria
Vassilis Aidinis
(Fleming Institute, Greece)
Autotaxin is a novel player in chronic inflammatory diseases and a promising therapeutic target
(Fleming Institute, Greece)
Autotaxin is a novel player in chronic inflammatory diseases and a promising therapeutic target
David N. Brindley
(University of Alberta, Canada)
Targeting the autotaxin-lysophosphatidate-inflammatory axis to improve the treatments of cancers
(University of Alberta, Canada)
Targeting the autotaxin-lysophosphatidate-inflammatory axis to improve the treatments of cancers
Charles E. Chalfant
(University of South Florida, USA)
The role of ceramide-1-phosphate in wound healing
(University of South Florida, USA)
The role of ceramide-1-phosphate in wound healing
Anastassis Perrakis
(Netherlands Cancer Institute, Netherlands)
Autotaxin: from structure - function relationships to rational design of allosteric inhibitors and back again
(Netherlands Cancer Institute, Netherlands)
Autotaxin: from structure - function relationships to rational design of allosteric inhibitors and back again
Ashley Cowart
(Virginia Commonwealth University, USA)
Sphingolipid functions in the diabetic heart
(Virginia Commonwealth University, USA)
Sphingolipid functions in the diabetic heart
Berit Johansen
(Norwegian University of Science and Technology, Norway)
Group IVA PLA2, a potent regulator of tissue fibrosis
(Norwegian University of Science and Technology, Norway)
Group IVA PLA2, a potent regulator of tissue fibrosis
Nicos A. Petasis
(University of Southern California, USA)
(University of Southern California, USA)
John Turk
(Washington University in St. Louis, USA)
Phenotypic properties of mice that do not express Group VIA PLA2 in selected tissues or globally
(Washington University in St. Louis, USA)
Phenotypic properties of mice that do not express Group VIA PLA2 in selected tissues or globally
Nicolas Bazan
(LSU Neuroscience Center, USA)
The elovanoids:
Novel pro-homeostatic lipid mediators
(LSU Neuroscience Center, USA)
The elovanoids:
Novel pro-homeostatic lipid mediators
Chemistry
Biology
BIOACTIVE
LIPIDS
Medicine